免疫检查点抑制剂用于治疗眼表面癌症:一篇评论
Wendy J Li1, Wisam Najdawi1, Omar Badla1
1Department of Ophthalmology, Bascom Palmer Eye Institute, Miami, FL, USA.
Seminars in ophthalmology
|February 9, 2025
概括
免疫检查点抑制剂 (ICI) 对结膜黑色素瘤和OSSN等眼表面瘤有前途,在传统治疗失败的地方提供了新的希望. 需要进一步的研究来克服挑战,并优化它们在这些罕见癌症中的使用.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 眼科医生 眼科 眼科
背景情况:
- 免疫检查点抑制剂 (ICI) 向免疫通路 (PD-1,PD-L1,CTLA-4,LAG-3) 以增强抗癌免疫力.
- 新兴研究探讨了ICI在眼皮表面瘤的疗效,包括结膜黑色素瘤 (CM) 和眼皮表面状瘤 (OSSN).
- 建议ICI在脂质腺癌 (SeC),结膜淋巴瘤和眼睛的卡波西肉瘤中也有潜在的作用.
研究的目的:
- 审查免疫检查点抑制剂 (ICI) 在治疗眼表面瘤中的作用.
- 在此背景下分析ICI的作用机制,临床结果和治疗潜力.
主要方法:
- 对2014年1月至2024年10月期间发表的研究进行了文献审查.
- 在PubMed数据库中搜索相关的原始研究,临床试验,病例报告和评论.
主要成果:
- 布利祖马布和尼沃卢马布在结膜黑色素瘤 (CM) 中表现出显著的疗效,在晚期病例中诱导瘤回归和稳定.
- 免疫检查点抑制剂 (ICI) 在眼表面状瘤 (OSSN) 中显示出有效性,特别是那些具有高瘤突变负担的瘤,导致部分或完全解决.
- 有限但有建议的数据表明,在耐火或晚期的脂质腺癌 (SeC) 和结膜淋巴瘤中,ICI的可能性很大.
结论:
- 免疫检查点抑制剂 (ICI) 为眼表面恶性瘤提供了转变的潜力,特别是在耐治疗或晚期疾病中.
- 挑战包括可变的反应率,与免疫相关的不良事件,以及对预测生物标志物的需求.
- 未来研究对于完善ICI应用,优化策略和改善这些罕见眼睛癌症的结果至关重要.
相关概念视频
Cancer Therapies
8.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.6K
Targeted Cancer Therapies
7.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.1K
Open Angle Glaucoma: Treatment
1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Angle Closure Glaucoma: Treatment
1.7K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.7K
Tumor Immunotherapy
2.6K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.6K
Ophthalmic Drug Delivery Systems
284
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
284


